Clinical trials for Lung cancer

278 currently recruiting clinical trials
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04777994
Escalade de dose (Tumeurs solides)
Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
Centre Antoine Lacassagne (Nice), Hôpital Foch (Suresnes), IUCT Oncopôle (Toulouse), Institut Paoli-Calmettes (Marseille)
Calico Life Sciences LLC
Phase 1 Lung cancer Stomach and esophageal cancer Head and neck cancer #NCT04389632
Partie C (Therapie combinée)
NSCLC (Non-Small Cell Lung Cancer) Esophagus Squamous cell carcinoma Locally Advanced Metastatic None Systemic Treatment-Naive
Immunotherapy
Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre Antoine Lacassagne (Nice), Institut de Cancérologie de Lorraine - Alexis Vautrin (Vandœuvre-lès-Nancy)
Seagen
Phase 1 Breast cancer Lung cancer Pancreas cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT04389632
Parties A et B (escalade de dose)
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Esophagus Invasive bladder cancer Epithelial ovarian cancer Squamous NSCLC Non-squamous NSCLC Adenocarcinoma Squamous cell carcinoma Urothelial carcinoma Serous high grade carcinoma (HGSOC) Other HER2 Negative Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre Antoine Lacassagne (Nice), Institut de Cancérologie de Lorraine - Alexis Vautrin (Vandœuvre-lès-Nancy)
Seagen
Phase 1 Breast cancer Lung cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Endometrial cancer Head and neck cancer #NCT05208762 #2023-506604-18-00
NSCLC (Non-Small Cell Lung Cancer) Stomach Esophagus Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses Squamous NSCLC Non-squamous NSCLC Adenocarcinoma Hepatocellular carcinoma Squamous cell carcinoma HER2 Negative HR Negative Locally Advanced Metastatic PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) 1 2 3 or more CPS Positive (1 <= X < 20) CPS Positive (X >= 20) CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Systemic Treatment-Naive
Institut Curie - Paris (Paris), Gustave Roussy (Villejuif), Groupe Hospitalier Saint André (Bordeaux)
Seagen
Phase 1 Breast cancer Lung cancer Stomach and esophageal cancer Head and neck cancer #NCT05208762 #2023-506604-18-00
NSCLC (Non-Small Cell Lung Cancer) Esophagus Oral cavity Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses Squamous cell carcinoma HER2 Negative HR Negative Locally Advanced Metastatic PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) 1 2 3 or more CPS Positive (1 <= X < 20) CPS Positive (X >= 20) CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Systemic Treatment-Naive
Institut Curie - Paris (Paris), Gustave Roussy (Villejuif), Groupe Hospitalier Saint André (Bordeaux)
Seagen
Phase 1 Lung cancer Head and neck cancer #NCT05208762 #2023-506604-18-00
NSCLC (Non-Small Cell Lung Cancer) Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Salivary glands Nasal cavities and sinuses Squamous cell carcinoma Locally Advanced Metastatic PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) 1 2 3 or more CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
Systemic Treatment-Naive
Institut Curie - Paris (Paris), Groupe Hospitalier Saint André (Bordeaux), Gustave Roussy (Villejuif)
Seagen
Phase 1 Lung cancer #NCT07015697
Partie 1 (Escalade de dose) et partie 2 (extension de dose) CBNPC, mutation HER2
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic HER2 1
Antibody Drug Conjugates (ADC) Antibody Drug Conjugates (ADC)
Centre François Baclesse (Caen ), CHU Amiens-Picardie (Amiens), Centre Eugene Marquis (Rennes), Institut de Cancérologie de l'Ouest - Site de Saint-Herblain (Saint-Herblain)
Daiichi Sankyo
Phase 1 Lung cancer #NCT04389632
Partie D (1L NSCLC)
NSCLC (Non-Small Cell Lung Cancer) Squamous NSCLC Non-squamous NSCLC Locally Advanced Metastatic None Systemic Treatment-Naive
Immunotherapy
Centre Hospitalier Universitaire de Poitiers - Site de la Milétrie (Poitiers), Centre Antoine Lacassagne (Nice), Institut de Cancérologie de Lorraine - Alexis Vautrin (Vandœuvre-lès-Nancy)
Seagen
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06026410
Bras 1 (Tumeurs solides avancées avec altération du gène RAS)
Locally Advanced Metastatic Other KRAS KRAS G12C KRAS non G12C NRAS HRAS KRAS G12D 1 2 3 or more
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris), IUCT Oncopôle (Toulouse)
Kura Oncologie, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT07094113
Parties 1, 2 et 3a
Locally Advanced Metastatic Other KRAS KRAS G12C KRAS non G12C KRAS G12D 1 2 3 or more
Systemic Treatment-Naive
Gustave Roussy (Villejuif), Centre Léon Bérard (Lyon)
Amgen